Adult Immunization

The dual PDE3/PDE4 inhibitor is the first inhaled product with a novel mechanism of action approved for COPD in 2 decades and is delivered via standard jet nebulizer.

Your daily dose of the clinical news you may have missed.

Capvaxive is the only pneumococcal vaccine formulated specifically to protect adults 50 years and older from IPD and elicited robust immune responses in both vaccine-naïve and vaccine-experienced adults.

The investigational combination vaccine elicited higher immune responses vs licensed comparator vaccines in 2 independent age groups, the company said.

GSK announced today approval by the US FDA of a label expansion for the adjuvanted RSV vaccine that adds adults aged 50 to 59 years who are at elevated risk for RSV disease to the vaccine’s current indication.

Your daily dose of the clinical news you may have missed.

mRESVIA is Moderna's second mRNA-based vaccine and will be shipped in prefilled syringes, a desirable feature that could save clinical time, prevent errors.

In STRIDE 10, V116 was superior to PPSV23 in adults aged ≥50 years and naive to pneumococcal vaccine for 8 of 9 serotypes unique to Merck's investigational shot.

Your daily dose of the clinical news you may have missed.

Vaccine efficacy remained high at 82% at year 11 following vaccination, according to new long-term data.

Your daily dose of the clinical news you may have missed.

The FDA expects to take action on the GSK BLA for its pentavalent MenB vaccine by February 14, 2025.

Nearly one-quarter of hospitalized adults aged 50 years and older with RSV experienced an acute cardiac event, according to results of a new study.

In adults hospitalized with RSV, odds of severe outcomes, including death, were much higher than for those admitted for, but vaccinated against, COVID-19, flu.

Pfizer plans to submit the phase 3 MONeT data to regulatory bodies in support of an expanded label for Abrysvo to include adults aged 18 to 59, the company said.

The study looked at the impact over 3 years but found that most of the averted burden, including more than 8000 fewer deaths, occur in the first year after vaccination.

The mRNA bivalent vaccine candidate produced a "more robust" immune response vs Spikevax and particularly in adults over the age of 65 years, said Moderna.

Respiratory vaccine R & D at Moderna, Merck, and Pfizer is focused on mRNA technology, added protection for vulnerable populations, and combination shots.

Long COVID affects approximately 20 million people in the US and that number may be conservative. Here, a snapshot, through the fog, of the route they are on.

The novel 21-valent pneumococcal vaccine remains on track for the FDA PDUFA date of June 17, 2024; Merck adds this new data to the body of positive evidence.

The bivalent vaccine demonstrated "durable efficacy" of more than 80% over 2 RSV seasons, according to Pfizer's report of topline findings from the RENOIR trial.

COVID-19 hospitalizations have never fall below 6000/week, according to the ACIP; those aged 65+ have the highest inpatient rate, those aged 75+ have the highest mortality.

Just when the new monovalent COVID-19 vaccines were available in Sept 2023, a new variant emerged. Did the CDC get it right? What do you know about the monovalent VE?

Approval of the application would extend the current Arexvy indication for prevention of RSV in adults aged 60 years and older; a June 2024 PDUFA date is set.

The National Foundation for Infectious Diseases medical director appeals to the community at large to set politics and personal grievance aside and to "first, do no harm."

Moderna's investigational vaccine against RSV in adults showed mean efficacy of 83% against the infection and is the only mRNA technology-based RSV shot.

If approved the 21-valent shot would be the first pneumococcal conjugate vaccine indicated specifically for adults.

First-ever vaccines against RSV in older adults, from GSK and Pfizer, won FDA approval in 2023. This brief slide show highlights the year's headline news about both.

Your daily dose of the clinical news you may have missed.

With 3 vaccines approved against pneumococcal disease in adults, is there really the need - or the room - for 1 more? Here's what one physician thinks.